Program
dapagliflozin
Also written as “Dapagliflozin”, “Dapagliflozin 10 mg” and “Dapagliflozin 10mg”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Renal Insufficiency, Chronic · Heart Failure · Diabetes Mellitus · Diabetes Mellitus, Type 1, led by 14 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 10910 open or running | phase 4since Jun 2, 2014 | Sep 9, 2005 | Dec 10, 2026phase 2 · NCT07222917 |
| LG Chem | 60 open or running | phase 3since Feb 2, 2020 | May 24, 2018 | none ahead |
| Boryung Pharmaceutical | 32 open or running | phase 1since May 26, 2022 | May 26, 2022 | none ahead |
| Dong-A ST | 20 open or running | phase 3since Apr 20, 2020 | Dec 5, 2018 | none ahead |
| Hansoh Pharmaceutical Group | 20 open or running | phase 1since Apr 30, 2021 | Apr 30, 2021 | none ahead |
| autotelicbio | 10 open or running | phase 1since Apr 20, 2021 | Apr 20, 2021 | none ahead |
| Daewoong Pharmaceutical | 10 open or running | phase 3since Nov 12, 2020 | Nov 12, 2020 | none ahead |
| Dexa Medica Group | 10 open or running | no phasesince Nov 7, 2023 | Nov 7, 2023 | none ahead |
| dong-wha-pharmaceutical-co-ltd | 10 open or running | phase 1since May 4, 2022 | May 4, 2022 | none ahead |
| George Clinical Pty | 10 open or running | phase 4since Nov 3, 2020 | Nov 3, 2020 | none ahead |
| Hamad Medical | 10 open or running | phase 3since Jul 22, 2018 | Jul 22, 2018 | none ahead |
| Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | 11 open or running | phase 3since Jun 16, 2025 | Jun 16, 2025 | none ahead |
| Novartis | 10 open or running | phase 2since May 21, 2021 | May 21, 2021 | none ahead |
| thpharm-corp | 10 open or running | phase 1since Sep 8, 2023 | Sep 8, 2023 | none ahead |
- Named in AstraZeneca’s own pipeline as
zibotentan/dapagliflozin
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: fortrea, parexel, ground-zero-pharmaceuticals, pt-equilab-international, Bristol-Myers Squibb, q2-solutions, pra-health-sciences, covance and antaros-medical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since Mar 15, 2016.
- Nov 5, 2024Phase 3 study in Heart FailureAstraZeneca · NCT06677060 · 11,300 planned · United States, Argentina, Australia and more
- Dec 16, 2024Phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT06742723 · 5,000 planned · United States, Argentina, Australia and more
- Apr 17, 2025Phase 2 study in Kidney DiseasesAstraZeneca · NCT06942910 · 224 enrolled · Russia
- May 5, 2025Phase 1 study in Lecithin Cholesterol Acyltransferase DeficiencyAstraZeneca · NCT06979388 · 14 enrolled · United Kingdom
- Jun 16, 2025Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair's first study: phase 3 study in Diabetes Mellitus, Type 2New to Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB ChairHan Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair · NCT07033585 · 600 enrolled · United States
- Jul 16, 20252 phase 1 studies in Diabetes MellitusBoryung Pharmaceutical · NCT07083401, NCT07083388
- Oct 17, 2025Phase 2 study in Renal Insufficiency, ChronicAstraZeneca · NCT07222917 · 222 enrolled · United States, Argentina, Bulgaria and more
- Nov 24, 2025Phase 1 study in Fed ConditionsLG Chem · NCT07333742 · 50 enrolled · South Korea
- Jan 23, 2026Phase 1 study in Healthy VolunteersLG Chem · NCT07399470 · 58 enrolled · South Korea
- Feb 2, 2026Phase 1 study in FastingLG Chem · NCT07396844 · 28 enrolled · Thailand
- Feb 5, 2026Phase 1 study in Renal Insufficiency, ChronicAstraZeneca · NCT07404137 · 26 enrolled · United States
- May 29, 2026Phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT07624305 · 2,800 planned · United States, Argentina, Austria and more
- Jun 18, 20262 phase 3 studies in Diabetes Mellitus, Type 2AstraZeneca · NCT07662109, NCT07662044
- Jul 13, 2026Phase 1 study in Renal InsufficiencyAstraZeneca · NCT07754331 · 10 enrolled · United States
Ahead
- Dec 10, 2026Primary completion: phase 2 study in Renal Insufficiency, ChronicAstraZeneca · NCT07222917
- Feb 18, 2027Primary completion: phase 3 study in Kidney DiseasesAstraZeneca · NCT06087835
- May 31, 2027Primary completion: phase 4 study in Renal Insufficiency, ChronicAstraZeneca · NCT06610526
- Feb 24, 2028Primary completion: phase 3 study in Renal Insufficiency, ChronicAstraZeneca · NCT06268873
TargetBeta
“The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Upon administration, dapagliflozin selectively targets and inhibits SGLT2, thereby preventing the reabsorption of glucose by the kidneys.”NCIt, read by Claude
“The propanediol form of dapagliflozin, a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity”NCIt, by rule
“Sodium/glucose cotransporter 2 inhibitor; Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule
Other programs on SLC5A2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| empagliflozinrule | Boehringer Ingelheim | phase 4 | 142 |
| ertugliflozinrule | Merck | phase 4 | 22 |
| Enavogliflozinrule | Daewoong Pharmaceutical | phase 3 | 25 |
| vicadrostat | Boehringer Ingelheim | phase 3 | 16 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
Studies
The newest 60 of 131 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07754331Renal Insufficiency · United States | 1 | Completed | AstraZeneca | Oct 6, 2026 | 10 |
| NCT07662109Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more | 3 | Recruiting | AstraZeneca | Jul 5, 2028 | 2,000 |
| NCT07662044Diabetes Mellitus, Type 2 · United States, Argentina, China and more | 3 | Recruiting | AstraZeneca | Jul 14, 2028 | 800 |
| NCT07624305Renal Insufficiency, Chronic · United States, Argentina, Austria and more | 3 | Recruiting | AstraZeneca | Jul 1, 2030 | 2,800 |
| NCT07404137Renal Insufficiency, Chronic · United States | 1 | Completed | AstraZeneca | Apr 2, 2026 | 26 |
| NCT07396844Fasting · Thailand | 1 | Completed | LG Chem | Jun 26, 2026 | 28 |
| NCT07399470Healthy Volunteers · South Korea | 1 | Completed | LG Chem | Feb 6, 2026 | 58 |
| NCT07333742Fed Conditions · South Korea | 1 | Completed | LG Chem | Nov 27, 2025 | 50 |
| NCT07222917Renal Insufficiency, Chronic · United States, Argentina, Bulgaria and more | 2 | Active, not recruiting | AstraZeneca | Dec 10, 2026 | 222 |
| NCT07083401Diabetes Mellitus · South Korea | 1 | Recruiting | Boryung Pharmaceutical | Jul 5, 2026 | 40 |
| NCT07083388Diabetes Mellitus · South Korea | 1 | Recruiting | Boryung Pharmaceutical | Jul 3, 2026 | 52 |
| NCT07033585Diabetes Mellitus, Type 2 · United States | 3 | Active, not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | Oct 18, 2026 | 600 |
| NCT06979388Lecithin Cholesterol Acyltransferase Deficiency · United Kingdom | 1 | Completed | AstraZeneca | Jul 12, 2025 | 14 |
| NCT06942910Kidney Diseases · Russia | 2 | Active, not recruiting | AstraZeneca | Sep 26, 2026 | 224 |
| NCT06742723Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Dec 18, 2029 | 5,000 |
| NCT06677060Heart Failure · United States, Argentina, Australia and more | 3 | Recruiting | AstraZeneca | Dec 17, 2029 | 11,300 |
| NCT06610526Renal Insufficiency, Chronic · China | 4 | Active, not recruiting | AstraZeneca | May 31, 2027 | 731 |
| NCT06268873Renal Insufficiency, Chronic · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Feb 24, 2028 | 2,554 |
| NCT06269484Liver Cirrhosis · United States, Australia, Belgium and more | 2 | Completed | AstraZeneca | Dec 11, 2024 | 73 |
| NCT06127212Healthy · Indonesia | – | Completed | Dexa Medica Group | Mar 15, 2023 | 24 |
| NCT06087835Kidney Diseases · United States, Argentina, Australia and more | 3 | Active, not recruiting | AstraZeneca | Feb 18, 2027 | 1,835 |
| NCT06063109Hypertension · South Korea | 1 | Completed | thpharm-corp | Nov 9, 2023 | 51 |
| NCT05516498Liver Cirrhosis · United States, Australia, Austria and more | 2 | Terminated | AstraZeneca | May 22, 2025 | 205 |
| NCT05411965Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Boryung Pharmaceutical | Jul 3, 2022 | 48 |
| NCT05403281Healthy Subjects · Korea, Republic of | 1 | Completed | dong-wha-pharmaceutical-co-ltd | Dec 3, 2021 | 41 |
| NCT05266404Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus) · Germany | 1 | Completed | AstraZeneca | May 31, 2022 | 46 |
| NCT04991571Renal Insufficiency, Chronic · United States | 1 | Completed | AstraZeneca | Oct 22, 2021 | 27 |
| NCT04899349Breast Neoplasms · United States, Malaysia | 2 | Terminated | Novartis | May 10, 2023 | 2 |
| NCT04881006Healthy Subjects · Canada | 1 | Completed | Hansoh Pharmaceutical Group | Dec 20, 2020 | 30 |
| NCT04880993Healthy Subjects · Canada | 1 | Completed | Hansoh Pharmaceutical Group | Dec 24, 2020 | 30 |
| NCT04856969Healthy Adult Volunteers · Korea, Republic of | 1 | Completed | autotelicbio | May 4, 2021 | 38 |
| NCT04856007Healthy Volunteer · China | 1 | Completed | AstraZeneca | Jun 14, 2021 | 80 |
| NCT04634500Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | Daewoong Pharmaceutical | Nov 3, 2021 | 200 |
| NCT04620590Diabetes Mellitus, Type 2 · United States, Canada | 4 | Completed | George Clinical Pty | May 30, 2023 | 17 |
| NCT04595370Heart Failure · United States, Belgium, Bulgaria and more | 2 | Completed | AstraZeneca | Sep 22, 2023 | 153 |
| NCT04564742Heart Failure · Sweden, United Kingdom | 3 | Completed | AstraZeneca | Jul 5, 2023 | 4,017 |
| NCT04544319T2DM | 1 | UNKNOWN | LG Chem | Mar 2021 | 44 |
| NCT04445714Diabetes Mellitus, Type 2 · India | 4 | Completed | AstraZeneca | Mar 14, 2023 | 196 |
| NCT04356742Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | Dong-A ST | Feb 23, 2022 | 198 |
| NCT04255238Diabetes Mellitus, Type 2 | 3 | UNKNOWN | LG Chem | May 30, 2022 | 468 |
| NCT03877237Heart Failure With Reduced Ejection Fraction (HFrEF) · United States, Brazil, Canada and more | 3 | Completed | AstraZeneca | Mar 7, 2020 | 313 |
| NCT03877224Heart Failure With Preserved Ejection Fraction (HFpEF) · United States, Argentina, Brazil and more | 3 | Completed | AstraZeneca | Jul 9, 2020 | 504 |
| NCT03766724Type2 Diabetes · Korea, Republic of | 1 | Completed | Dong-A ST | Jan 18, 2019 | 42 |
| NCT03619213Heart Failure With Preserved Ejection Fraction · United States, Argentina, Belgium and more | 3 | Completed | AstraZeneca | Mar 27, 2022 | 6,263 |
| NCT03658031Prediabetic State · Qatar | 3 | UNKNOWN | Hamad Medical | Dec 31, 2020 | 576 |
| NCT03608358Diabetes Mellitus, Type 2 · Thailand, Vietnam | 3 | Terminated | AstraZeneca | Aug 4, 2020 | 41 |
| NCT03565458Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | UNKNOWN | LG Chem | Aug 20, 2018 | 48 |
| NCT03387683Diabetes Mellitus, Type 2 · Finland, Sweden | 4 | Completed | AstraZeneca | Mar 19, 2019 | 53 |
| NCT03344341Diabetes Mellitus, Type 2 · China | 4 | Terminated | AstraZeneca | May 24, 2019 | 304 |
| NCT03338855Diabetes Mellitus, Type 2 · Netherlands | 4 | Completed | AstraZeneca | Nov 4, 2019 | 26 |
| NCT03199053Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Feb 1, 2023 | 256 |
| NCT03169959Diabetes Mellitus, Type 2 · United States | 1 | Completed | AstraZeneca | Aug 3, 2017 | 85 |
| NCT03138356Diabetes Mellitus, Type 2 · United Kingdom | 1 | Completed | AstraZeneca | Nov 28, 2017 | 126 |
| NCT03152084Diabetes Mellitus, Type 2 · Netherlands, Sweden | 4 | Terminated | AstraZeneca | Mar 20, 2020 | 24 |
| NCT03216278Lecithin Cholesterol Acyltransferase Deficiency · Brazil | 1 | Completed | AstraZeneca | May 22, 2018 | 284 |
| NCT03036150Renal Insufficiency, Chronic · United States, Argentina, Brazil and more | 3 | Completed | AstraZeneca | Jun 12, 2020 | 4,304 |
| NCT03036124Heart Failure · United States, Argentina, Brazil and more | 3 | Completed | AstraZeneca | Jul 17, 2019 | 4,744 |
| NCT02725593Diabetes Mellitus, Type 2 · United States, Hungary, Israel and more | 3 | Completed | AstraZeneca | Apr 6, 2020 | 72 |
| NCT02719132Diabetes Mellitus, Type 2 | 4 | Withdrawn | AstraZeneca | Nov 2017 | 0 |
| NCT02722239Diabetes Mellitus, Type 2 · Russian Federation | 1 | Completed | AstraZeneca | May 5, 2016 | 40 |
How it is read
Names in the registry
- “Dapagliflozin”, 90 entries
- “dapagliflozin”, 18 entries
- “Dapagliflozin 10 mg”, 6 entries
- “Dapagliflozin 10mg”, 5 entries
- “Dapagliflozin/metformin XR 10/1000mg”, 4 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 80 studies
- Renal Insufficiency, Chronic, 8 studies
- Heart Failure, 7 studies
- Diabetes Mellitus, 7 studies
- Diabetes Mellitus, Type 1, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.